Skip to Content
Merck
All Photos(1)

Key Documents

SAB4700486

Sigma-Aldrich

Monoclonal Anti-CD138, azide free antibody produced in mouse

clone B-A38, purified immunoglobulin, buffered aqueous solution

Synonym(s):

Anti-SDC1, Anti-Syndecan 1

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

conjugate

unconjugated

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

B-A38, monoclonal

form

buffered aqueous solution

species reactivity

human

concentration

1 mg/mL

technique(s)

flow cytometry: suitable

isotype

IgG1

NCBI accession no.

UniProt accession no.

shipped in

wet ice

storage temp.

2-8°C

target post-translational modification

unmodified

Gene Information

human ... SDC1(6382)

General description

Cluster of differentiation 138 (CD138), also known as syndecan 1, is a cell surface heparan sulfate proteoglycan. It is encoded by the gene mapped to human chromosome 2p21-p25. The encoded protein belongs to SDC family and is exclusively expressed on epithelial cells. Members of SDC protein family contain an extracellular domain carrying heparan sulfate, a transmembrane domain and a cytoplasmic domain.
The antibody B-A38 recognizes CD138 (syndecan 1), a 65-70 kDa heparan sulfate proteoglycan expressed mainly in the epidermis and plasma cells, but also in growth factor-stimulated lymphocytes.

Immunogen

U266 human peripheral blood myeloma cell line

Application

The reagent is designed for Flow Cytometry analysis. Suggested working dilution for Flow Cytometry is 3-5 μg/mL of sample. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.

Biochem/physiol Actions

Cluster of differentiation 138 (CD138) along with α2β1 integrin binds to collagen I and regulates cell motility. The encoded protein functions as a coreceptor for variety of biological factors such as, growth factors, angiogenic factors, cytokines and chemokines. CD138 acts as a potential marker for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients. Genetic variations in the gene is associated with the development of breast cancer. Thus, CD138 can be considered as a potential therapeutic target for inflammatory breast cancer (IBC).

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Solution in azide free phosphate buffered saline, pH 7.4; 0.2 um filter sterilized.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients
Gharbaran R
Journal of Hematology & Oncology (2013)
Anita Murer et al.
PLoS pathogens, 14(4), e1007039-e1007039 (2018-05-01)
The oncogenic Epstein Barr virus (EBV) infects the majority of the human population and usually persists within its host for life without symptoms. The EBV oncoproteins nuclear antigen 3A (EBNA3A) and 3C (EBNA3C) are required for B cell transformation in
Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways
Ibrahim SA
Molecular Cancer, 16 (2017)
Sdc1 Negatively Modulates Carcinoma Cell Motility and Invasion
Ishikawa T and Kramer RH.
Experimental Cell Research, 316, 951-965 (2010)
Recurrent gene amplifications in human type I endometrial adenocarcinoma detected by fluorescence in situ hybridization
Samuelson E
Cancer Genetics and Cytogenetics, 181, 25-30 (2008)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service